The intracellularly surviving and slow-growing pathogen, Mycobacterium tuberculosis, adapts the host cell environment for its active and dormant life cycle. It is evident that the lack of appropriate highthroughput screening of inhibitors within host cells is an impediment for the early stages of anti-tubercular drug discovery. We aimed to develop an integrated surrogate model that enhances the screening of large inhibitor libraries.
Introduction
Tuberculosis (TB) is an ancient infectious disease that is still responsible for the highest human mortality worldwide from its single causal pathogen, Mycobacterium tuberculosis. 1 In spite of intensive efforts towards eradicating TB, it remains a challenging problem, not only for developing countries but also for the developed world. According to the latest data, 1.6 million deaths from TB have been reported. 1 Furthermore, the situation is becoming even more complicated due to issues such as (i) long, complex and ineffective chemotherapy against newly emerging, extensively drug-resistant (XDR)/totally drug-resistant (TDR) TB strains, and (ii) incompatibilities between anti-TB and anti-HIV drugs. Therefore, development of a new and more effective drug treatment against TB is urgently required.
A concerted effort has been recently made worldwide towards developing new anti-TB drugs by different consortia and organizations, such as the TB Alliance (http://www. tballiance.org/), TBD UK (http://www.tbd-uk.org.uk/), Open Source Drug Discovery (OSDD) (http://www.osdd.net/), New Medicines For Tuberculosis (NM4TB) (http://www.nm4tb.org/), the Working Group on New TB Drugs (WGND) (http://www.newtbdrugs.org/) and More Medicines for Tuberculosis (MM4TB) (http://www. mm4tb.org/), resulting in a large number of novel chemical libraries in the pipeline waiting for comprehensive evaluation at the preclinical stage of TB drug development. 2 -6 During infection, M. tuberculosis is able to survive inside the host's primary immune cells even under different stress conditions for an undefined period. 7 Whilst the standard practice for screening inhibitors is to test them against actively dividing bacilli in vitro, most growth inhibitor hits fail at a later stage of the extremely expensive in vivo clinical trials. 8 Furthermore, the slow growth, highly infectious nature of M. tuberculosis and the complex infrastructure pose major obstacles towards developing a comprehensive high-throughput, intracellular, drug screening procedure.
To avoid the use of the highly pathogenic, slow-growing M. tuberculosis in the early drug screening process, different mycobacterial species, such as Mycobacterium smegmatis, 9 Mycobacterium fortuitum, 10, 11 Mycobacterium phlei, 11 Mycobacterium aurum, 10 Mycobacterium abcessus, 11 Mycobacterium marinum 12 and Mycobacterium bovis BCG 13 have been utilized as surrogates. Of these, the non-pathogenic fast-growing M. aurum possesses a similar cell wall profile to M. tuberculosis, 14 as well as sharing intracellular therapeutic targets, 15 gene organization 16 and drug resistance patterns. 17 Here, we compared M. aurum with M. smegmatis mc 2 155, Mycobacterium neoaurum (another species of the M. aurum clade) and M. bovis BCG for suitability in drug screening systems. M. smegmatis mc 2 155, which does not provide a consistent and reliable model for drug screening, was chosen as a negative control because it does not have the ability to survive inside macrophages. 18 Mouse macrophage cell line RAW 264.7 has been considered suitable for drug screening because of its high phagocytic activity, adherence capability and ease of culturing. 19 The choice of mouse macrophages is also supported by the wide use of mice as an animal model for in vivo anti-TB drug testing. We have previously used the spot culture growth inhibition (SPOTi) assay, a solid agar-based method that has advantages in drug screening over liquid-based colorimetric assays, and methods that employ cfu counting (the 'gold standard' quantification method). 20, 21 In this study, we have integrated M. aurum (a surrogate for M. tuberculosis), RAW 264.7 macrophages (surrogates for primary immune cells) and SPOTi (a method for testing inhibitors) to develop a rapid and convenient intracellular-screening platform. This is the first report of such a comprehensive model for testing inhibitor libraries.
In developing the surrogate method for screening novel antimycobacterials against M. tuberculosis within a host cell environment, our objectives were: (i) to validate M. aurum as a good intracellular model for testing bacteriological inhibitors; (ii) to characterize the uptake and survival of M. aurum inside RAW 264.7 macrophage cells; and (iii) to examine the reliability of the screening system using known anti-TB drugs on M. aurum inside the RAW 264.7 macrophages.
Materials and methods

Selected anti-TB drugs
The known anti-TB front-line drugs [isonicotinic acid hydrazide (isoniazid), rifampicin, pyrazinamide and ethambutol] and second-line drugs (ethionamide, p-aminosalicylic acid, D-cycloserine, streptomycin, ofloxacin, phosphomycin, cephalosporin and metronidazole) were bought from Sigma. Isoniazid, streptomycin and cephalosporin were dissolved in water, and the others were dissolved in DMSO, to a concentration of 50 g/L. All antibiotics were sterilized using 0.2 mm filters (Sartorius). All chemicals were purchased from Sigma, unless otherwise stated. 
Growth and maintenance of mycobacterial species
Development of a higher throughput extracellular SPOTi assay
The solid agar-based MIC-determining SPOTi screening method 20, 21 was extended from a 6-well to a 24-well format. 
Growth inhibition of mycobacteria at different pH
M. neoaurum and M. aurum cultures (OD 600 ≈1.0) were harvested, and 2 mL of cells (undiluted, ×10 and ×100 diluted) were spotted on Petri dishes containing Sauton's agar medium. The Sauton's agar medium was prepared by adding 4.0 g L-asparagine, 2.0 g citric acid, 0.5 g KH 2 PO 4 , 0.5 g MgSO 4 . 7H 2 O, 0.05 g ferric ammonium citrate, 15.0 g agar and 60 mL glycerol in deionized water. It was adjusted to different pH values (5.5, 5.8, 6.0, 7.0 and 7.2) using 5 M NaOH. The volume was adjusted to 1 L and then sterilized. To observe the antibiotic susceptibility under acidic stress, M. neoaurum cells (OD 600 ≈1.0) were washed with PBS (pH 7.0) twice before being stressed by placing in acidic Sauton's liquid medium for 1 h at 378C. 23 Stressed cells (2 mL, 10 6 cells/mL) were spotted onto 24-well plates containing Sauton's agar medium at pH 5. and 10% heat-inactivated fetal bovine serum (378C, humidified 5% CO 2 )], and passaged twice before the assay. Before passage, cells were washed twice with 1× PBS to remove unattached cells. Adhered cells were detached using a lidocaine/EDTA mixture (10 mM lidocaine HCl, 10 mM EDTA in 1× PBS) at room temperature for 10 min followed by hitting the side of the flask against the palm of the hand, and then diluting with an equal volume of fresh medium. 20 Cells were then centrifuged at 1000 g for 5 min and resuspended in fresh medium. The number of viable cells was counted using a Trypan Blue assay. Stock cultures of the cells were maintained at 2808C by adding actively growing cells to an equal volume of Bambanker TM Cell Freezing Media (Anachem).
Cell toxicity assay using RAW 264.7 macrophages stock solutions of antimicrobial compounds were placed in wells containing 200 mL of RPMI-1640 complete medium in the first row, and then 2-fold serial dilution was done six times (the last well did not contain any antibiotic and was used as the control). To each well, 100 mL of diluted macrophage cells (5×10 5 cells/mL) was added. After 48 h of incubation, the monocytes were washed twice with PBS, and fresh RPMI-1640 complete medium was added. Plates were then treated with 30 mL of a freshly prepared 0.01% resazurin solution and incubated overnight at 378C. The following day the change in colour was observed and the fluorescence intensity was measured (l ex 560 nm, l em 590 nm, FLUOstar OPTIMA microplate reader; BMG LABTECH GmbH). 4 The 50% growth inhibitory concentration (GIC 50 ) was determined based on a resazurin fluorescence assay, and the selectivity index (SI) was determined, as the ratio between the GIC 50 against RAW 264.7 macrophages and the MIC against M. aurum, for all tested drugs.
Optimizing the uptake of mycobacteria in RAW 264.7 macrophages M. smegmatis mc 2 155, M. neoaurum, M. aurum and M. bovis BCG were labelled with fluorescein 5(6)-isothiocyanate (FITC) by adding 10 8 -10 9 cells to 1 mL of 0.01% FITC in 0.5 M carbonate/bicarbonate buffer pH 9.5 (0.5 M Na 2 CO 3 , 1 volume; 0.5 M NaHCO 3 3 volumes) and incubating for 30 min at 258C. 20 The bacteria were then washed twice in RPMI-1640 complete medium to remove surplus dye and suspended in RPMI-1640 complete medium. Macrophages (100 mL, 1×10 6 cells/ mL) in a 96-well clear-bottom black plate (Corning, Appleton Woods) were infected with an equal number of unlabelled and labelled bacilli at 10: 1 multiplicity of infection (moi) ratio. At 2 h post-infection, the infected macrophages were washed with PBS containing 0.05% Tween 80, and this was followed by a wash with PBS alone. Cells were then suspended in 100 mL of PBS and the fluorescence was measured (l ex 485 nm, l em 520 nm). For optimizing the uptake of M. aurum, macrophage cells were infected with unlabelled and labelled bacilli at different mois (5: 1, 10: 1 and 20 : 1) at 2 h post-infection, and at different timepoints (0, 30, 60 and 120 min) with a fixed moi (10 : 1). Onlymacrophages and only-bacteria wells were used as controls, and only-PBS/RPMI-1640 was used as a blank. Fluorescence per mg of protein was calculated by equating the fluorescence intensity with protein concentration of the respective well. The protein concentration was measured using the Bradford colorimetric assay.
Optimizing the infection of M. aurum in RAW 264.7 macrophages
A macrophage cell suspension was adjusted to 1×10 6 cells/mL, and 2 mL was added onto circular coverslips (Appleton Wood) of 6-well cell culture flat-bottom plates. After 15 min of incubation, 10, 20 or 40 mL of mid-log phase M. aurum cells (1×10 9 cells/mL) harvested in RPMI-1640 complete medium were added to each well at different mois (5:1, 10:1 and 20:1) 2 h post-infection, and at different times (30, 60 and 120 min) with a fixed moi (10:1). Treated coverslips were washed thrice with RPMI-1640 medium containing 0.05% Tween 80 and assessed by ZN staining using a TB-colour staining kit. Co-infection was optimized by counting bacteria per macrophage cell under a bright field microscope (Zeiss) with coverslips mounted onto slides. Acid fast-stained phagocytosed mycobacteria images were captured at ×1000 magnification.
Optimizing the survival of M. aurum in RAW 264.7 macrophages
For the survival assay, macrophages cells infected with M. aurum were lysed at different times (0, 24, 48 and 72 h) in distilled water at room temperature for 10 min followed by scrubbing using a syringe plunger. The lysed cells were spread onto plates containing MB7H10 OADC agar, and then incubated at 378C to determine the cfu.
Development of 24-well plate SPOTi assay with RAW 264.7 macrophages
For the killing assay, macrophages (5×10 5 cells per well) were infected with M. aurum at 10: 1 moi for 1 h at 378C in a 24-well plate. The culture was washed with RPMI-1640 thrice and incubated with different concentration of inhibitors (0, 0.39, 1.5, 6.25, 25 and 100 mg/L) in RPMI-1640 complete medium. Inhibitors were incubated for different times (2 h, 24 h, 48 h and 72 h). Cells were then washed twice with RPMI-1640 and lysed in 500 mL of distilled water at room temperature for 10 min. The lysed cells were centrifuged and suspended in 50 mL of distilled water. Then, 5 mL was spotted onto wells of a 24-well plate containing MB7H10/OADC/agar and incubated at 378C for 5 days to determine intracellular survival.
Results
M. aurum as a bacteriological model for testing antimycobacterials
Comparative growth curves of mycobacterial species
Based on cell morphology, generation time, antibiotic susceptibility and intracellular survival ability, we compared M. smegmatis mc 2 155, M. neoaurum, M. aurum and M. bovis BCG in order to establish a bacteriological model for this study. The mycobacterial species were first observed for their morphology using cold ZN staining. M. neoaurum and M. aurum showed a similar pattern to M. bovis BCG, while M. smegmatis mc 2 155 cells were more elongated (acid fast-stained cells at mid-log phase; Figure 1 ). The mycobacterial species were also studied for their physiological properties by plotting their growth curves (OD 600 against time). As both M. neoaurum and M. aurum are scotochromogenic species, a spectrum analysis was performed to exclude possible interference by chromogenic substrate at 600 nm. The growths of mycobacterial species were observed at three different growth rates: active, moderate, and slow. Although M. smegmatis mc 2 155 and M. neoaurum showed the fastest growth, comparative growth curves showed that M. aurum also take less time to enter the log phase compared with M. bovis BCG (Figure 1 ). For M. aurum, logphase cells were collected after 36 h, SPOTi assays were performed after 5 days and colonies were obtained on plates after 8 days; for M. bovis BCG the corresponding values were 3-4 days, 14 days and 28 days ( Table 1) .
Growth of mycobacterial species in the presence of anti-TB drugs (MIC)
A solid agar-based SPOTi assay was performed in a 24-well plate format ( Figure 2 ). The MICs of known antibiotics were determined for complete inhibition for M. smegmatis mc while the other three, phosphomycin, metronidazole and pyrazinamide, were not active ( Table 2) .
Tolerance of mycobacterial species to pH
In order to select an intracellularly survivable bacteriological model, M. neoaurum and M. aurum were analysed at acidic pH Generation time was calculated according to (t22 t1)×ln(2)/ln(q2/q1) where t2 is the final time, t1 is the beginning of growth (end of lag phase), q2 is the cell number at t2, and q1 is the cell number at t1.
for their survival ability, and the results were compared with earlier reports for M. smegmatis mc 2 155, M. bovis BCG and M. tuberculosis H37Rv. 24 We found that, similarly to M. bovis BCG and M. tuberculosis H37Rv, M. aurum was sensitive to acidic pH (Figure 3b ): growth was undetected at ≤pH 6.0, and full growth was seen only at pH 7.2 ( Figure 3b ). In contrast, similarly to M. smegmatis mc 2 155, M. neoaurum was not sensitive to pH 5.8, 6.0, 7.0 or 7.2, but we observed retarded growth at pH 5.5 ( Figure 3a) . We also performed the anti-TB drug susceptibility test against M. neoaurum in acidic stress conditions (pH 5.5-7.0) and found that the rifampicin, D-cycloserine and cephalosporin had increased effectivity in acidic conditions (Table 3) , which indicates higher antibiotic susceptibility at low pH. We also observed modulation in MICs between an enriched medium (MB7H10) and minimal medium (Sauton's) (Tables 2 and 3 ). Rifampicin, p-aminosalicylic acid, cephalosporin and ofloxacin were more active against M. neoaurum in enriched medium while isoniazid was more active against M. neoaurum in minimal medium.
RAW 264.7 for an ex vivo infection model
We observed that monolayers of RAW 264.7 spread uniformly, adhered well and started differentiating into active macrophages within 15 min. The 80% viability of macrophage cells was determined by using a Trypan Blue assay.
Toxicity of anti-TB drugs against RAW 264.7
Macrophages in logarithmic growth phase were used for testing the cytotoxicity of various antibiotics against RAW 264.7 macrophage cells before testing compounds for intracellular inhibition. All anti-TB drugs were found to be non-toxic to RAW 264.7 macrophages, as determined by GIC 50 values (cephalosporin 500 mg/L, rifampicin 700 mg/L, ethionamide 1000 mg/L, ofloxacin 1500 mg/L and others ≥3000 mg/L), resulting in SI values .20 for all drugs tested (Table 4) .
Uptake of mycobacterial species into RAW 264.7 macrophages
When phagocytosis of M. smegmatis mc 2 155, M. neoaurum, M. aurum and M. bovis BCG were compared by an FITC fluorescence uptake assay (2 h infection time), we found that M. aurum had similar uptake to M. bovis BCG, while M. smegmatis mc 2 155 and M. neoaurum had 3 -5 times lower uptake (Figure 4c ). This further supported the selection of M. aurum as a fast-growing mycobacterial model organism for drug screening.
Infection of M. aurum within RAW 264.7 macrophages
A small aliquot of M. aurum culture was used for screening against extracellular bacilli by performing a SPOTi assay, and the remainder was used further to optimize the uptake and killing assay. Uptake of M. aurum was assessed using ZN staining of infected and noninfected macrophages, and by a quantitative fluorescence assay. Staining results showed the presence of engulfed pink (carbolfuchsin-stained) M. aurum inside blue (methylene-blue-stained) macrophage cells ( Figure 5 ). Phagocytosis was observed between 30 min and 2 h (moi 10:1), while increasingly clumped bacilli were seen with increasing moi at fixed timepoints ( Figure 5 ).
Quantitative analysis of unlabelled and FITC-labelled M. aurum-infected macrophages showed that maximum uptake was observed at 10 :1 moi and 1 h infection time (Figure 4a and b) .
Killing of M. aurum within RAW 264.7 macrophages
Intracellular survival was evaluated by cfu counting in the absence or presence of a subinhibitory concentration of isoniazid (Figure 4d ). M. aurum was able to survive intracellularly and entered into logarithmic growth phase in 48 h, with a 10-fold increase in bacilli in the following 24 h (Figure 4d Figure 3 . Growth of (a) M. neoaurum and (b) M. aurum in plates containing Sauton's medium of different pH (5.5 -7.2). The assay was performed with three biological replicates. drugs (isoniazid, rifampicin, pyrazinamide and ethambutol) using the SPOTi assay ( Figure 6 ). Significant inhibition by isoniazid and rifampicin was observed after 24 h, and complete inhibition was observed after 48 h. Therefore, a 48 h drug-incubation timepoint was chosen for our model ( Figure 7 ). In conclusion, the M. aurum with murine macrophage high-throughput drug-screening model was optimized with the following parameters: 10: 1 moi uptake, 1 h infection, and 48 h drug incubation. Intracellular MICs of all anti-TB drugs (isoniazid, rifampicin, pyrazinamide, D-cycloserine, p-aminosalicylic acid, cephalosporin, ethionamide, ethambutol, streptomycin and ofloxacin) for phagocytosed M. aurum were calculated, except phosphomycin and metronidazole, which were not active against extracellular mycobacteria. We found that rifampicin, p-aminosalicylic acid, ethionamide, streptomycin and ofloxacin had slightly higher MIC values when inside the macrophages compared with extracellular values, while ethambutol was more active inside macrophages. It is noteworthy that pyrazinamide was not active and p-aminosalicylic acid was considerably less active against intracellular M. aurum, although the extracellular MIC of the latter was 1 mg/L (Table 4) .
Discussion
During pathogenesis, M. tuberculosis cells enter the alveolar macrophage cells of the host, and are often able to survive in a nutrient-deficient, oxygen-deficient, redox-active and highly acidic environment, in various physiological states (replicating, not replicating or slowly replicating) for an undefined period of time. 7 Therefore, it is important to have an inhibitor screening assay for these different physiological bacilli states within the host cell environment. In addition, the solubility, permeability, stability and eukaryotic cell toxicity of novel chemical entities are also relevant for antibacterial selectivity and subsequent progress through the drug development pipeline. Considering these, our study aimed to establish an integrated high-throughput method for testing libraries of compounds for in-cell growth inhibition of mycobacteria.
The use of the fast-growing, non-pathogenic, biosafety level 2 organism M. aurum as surrogate model organism provides a rapid, less hazardous and more economic platform for the primary screening of inhibitors. Based on the similarity of its gene organization and enzymatic activity to those of M. tuberculosis, recombinant M. aurum has already been established as a model for screening inhibitors targeting known pathways. 16, 17 RAW 264.7 cells were found to have better growth kinetics and ability to phagocytose mycobacteria than other cell lines. 19 Our results further support the identification of M. aurum as an appropriate screening model for M. tuberculosis over other tested fast-growing species, such as M. smegmatis mc 2 155 and M. neoaurum. In addition, the adaptation of the SPOTi method to a 24-well plate format provided further saving of resources, including consumption of inhibitors. The direct observation of growth inhibition in the SPOTi method affords reliability and reproducibility of results, superior to other available methods where growth can be compromised by contaminants (radioactivity, fluorescence or colorimetric counts in automated systems). Furthermore, the SPOTi method saves time compared with the authenticated but laborious gold standard method, cfu counting. The compatability of the SPOTi assay with differing media components and pH in minimal media was shown, and it can be utilized for assaying actively dividing bacilli as well as mycobacteria in various physiological growth conditions, such as the Hu et al. 25 models of dormant and drug-tolerant mycobacteria, the Wayne and Hayes 26 dormancy model, the oxygen-depletioninduced model 27 and the chemostatic model. 28 Furthermore, this SPOTi-based model can be used to screen against drug-resistant as well as genetically modified mycobacteria. 17 High-throughput screening of anti-tuberculars Moreover, the natural pigmentation of M. aurum helps to distinguish its spots from mycobacterial contaminants (if present).
Extracellular antibiotic-susceptibility profiles of first-and second-line anti-tubercular drugs against M. aurum showed close similarity to the MICs for M. tuberculosis H37Rv (Table 2) . We found that the sensitivity of M. aurum, unlike M. neoaurum and M. smegmatis, to acidic pH is similar to that of M. tuberculosis H37Rv (Figure 3) . We further justified the use of M. aurum for testing of inhibitors within infected macrophages (which are known to be acidic). Moreover, similar uptake of M. aurum and M. bovis BCG into macrophages (Figure 4c ) provided additional validation of M. aurum as an appropriate fast-growing, intracellularly surviving surrogate.
The developed model involves screening inhibitors against extracellular bacilli and host macrophages, and then screening against intracellular populations. Using an optimized SPOTibased M. aurum intracellular model, MIC patterns showed differences in drug susceptibility between actively dividing extracellular bacilli and bacilli at different physiological stages inside the host macrophage cells (Table 4) . Interestingly, mycobacteria showed no such difference in susceptibility to pyrazinamide, and susceptibility to p-aminosalicylic acid was significantly lower inside macrophages.
Pyrazinamide, a front-line anti-TB drug was found to be ineffective against actively dividing mycobacteria in vitro, yet active in a mouse model. 30 In this study, pyrazinamide was found to be inactive both against M. neoaurum grown in culture medium at acidic pH and against M. aurum grown inside macrophages. Therefore, the effect of the intracellular environment and the requirement for the presence of other anti-TB drugs for the activation of the pro-drug are still debatable. 31, 32 p-Aminosalicylic acid is a second-line anti-TB drug reported to have more than one intracellular target. As a metabolic analogue, p-aminosalicylic acid inhibits the tetrahydrofolate pathway, and as an antisalicylate compound, it interferes with the conversion of salicylic acid to carboxymycobactin and mycobactin (ionophores for iron transport). We observed that only p-aminosalicylic acid showed a significant difference in activity against M. neoaurum when tested in two different culture media (Sauton's and MB7H10) ( Tables 2 and 3 ). We infer, as MB7H10 medium has 8 times higher iron concentration than Sauton's medium, that more p-aminosalicylic acid is needed to inhibit iron uptake. 33, 34 p-Aminosalicylic acid inhibits the uptake of iron by targeting mycobactin. We also found that p-aminosalicylic acid was not active against M. smegmatis mc 2 155 or M. neoaurum, while it was active against M. aurum and M. bovis BCG ( Table 2) . In an earlier study it was found that M. smegmatis mc 2 155, unlike M. tuberculosis H37Rv or M. bovis BCG, has a second, salicylic acid-independent route of iron uptake; therefore, it is less susceptible to p-aminosalicylic acid. 35 Results in this study indicate that M. aurum has an iron uptake mechanism similar to that of M. bovis BCG and M. tuberculosis H37Rv, while the mechanism in M. neoaurum is similar to that in M. smegmatis mc 2 155. We have found that p-aminosalicylic acid loses its activity against M. aurum inside the macrophages; this supports a previous finding where no intracellular activity was detected in a mouse model. 36 The integration of M. aurum-infected RAW 264.7 mouse macrophage cells with the SPOTi assay to yield a cost-effective and low-hazard microbiology containment system now provides an effective inhibitor screening method to address the large number of compound libraries, thus facilitating early stage anti-TB drug discovery.
